TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07816185: A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)

Sponsor: Pulmovant, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 376 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07816185 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07816185 Rescue Dossier →